Commercial Stage Products
We aim to expand the business in synergistic therapeutic areas to enlarge our product portfolio and to increase critical mass in the geographies where Chiesi already is present.
In Europe, Chiesi is focused on expanding business in synergistic therapeutic areas and on developing business opportunities for our Affiliates:
-
Assets acquisition or In-licensing in-market products in the field of Respiratory, Special Care (including Orphan Drugs)
-
Asset acquisition or In-licensing in-market products in the field of Consumer Healthcare (OTC / OTX)
Overwiew
3,800
Total Staff
1,600
Commercial Staff
€ 1,100 M
Turnover
Focus
Respiratory, Neonatology, Transplantology, and Tare Diseases
In the USA, Chiesi is looking for products in the hospital space and in rare diseases. Within thehospital space, the interest lies primarily in acute cardiovascular diseases, hematology, allergy/immunology, and nephrology.
Overwiew
250
Total Staff
130
Commercial Staff
€ 300 M
Turnover
Focus
Hospital setting products (neonatology, acute cardiovascular care and cystic fibrosis)
In other markets, Chiesi is focusedon expanding business in synergistic therapeutic areas and to develop business opportunities for our Affiliates:
Assets acquisition or in-licensing in-market products in the field of Respiratory, Special Care (including Orphan Drugs) Company acquisition to increase critical mass in the geography whereChiesi branches already exist (Brazil, China, Mexico, Pakistan, Russia, CIS, Turkey)
Overwiew
1200
Total Staff
800
Commercial Staff
€ 300 M
Turnover
Focus
Respiratory, neonatology, and hospital setting product
We are looking to partner with companies developing innovative therapeutic assets and platforms that can provide significant benefits to patients, healthcare providers, and payers across our core therapeutic areas: respiratory, rare diseases and special care, and neonatology.
Respiratory
Chiesi is looking for products in all development stages for:
- Asthma/Chronic Obstructive Pulmonary Disease
- Idiopathic Pulmonary Fibrosis
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Cystic Fibrosis
- Chronic Cough
- Chronic Cough
- Non-Cystic Fibrosis Bronchiectasis
- Acute Respiratory Distress Syndrome
Link to recent PR and acquisitions:
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP
Neonatology
Chiesi is looking for opportunities in all development stages for:
- Neonatal Respiratory Distress Syndrome
- Bronchopulmonary Dysplasia
- Neonatal brain injury
- Neonatal Abstinence Syndrome
Link to recent PR and acquisitions:
Rare Diseases and Special Care
Chiesi is looking for opportunities in the following therapeutic areas, with priority given to projects in clinical development, or ready to enter clinical development:
- Lysosomal storage Disorders
- Other Rare Diseases with significant unmet medical need, in particular in the metabolic space
- Transplantation
- Nephrology
Link to recent PR and acquisitions:
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
As part of our mission to deliver care to people with conditions, we are actively pursuing technologies and platforms that allow us to provide evidence-backed, non-pharmacological interventions targeted at health outcomes via behavior change.
We are also looking for platforms that can enhance our existing product development and commercialization processes. To do so, we engage with partners through a variety of structures such as licensing agreements, co-promotion/distribution, acquisitions, and equity investments.
An example of such a partnership is with Kaia Health, Start Up Health and Aptar.
We are actively seeking partnerships with researchers from leading universities, academic medical centers, research institutes and centers of excellence in pulmonary care and neonatal intensive care worldwide.
We look forward to hearing from researchers and physician-scientists working in these areas of interest who are keen to collaborate with us.